Effect of the Hirudin Carboxy-Terminal Peptide 54-65 on the Interaction of Thrombin with Platelets

Summary

The carboxy-terminal region of hirudin (residues 54-65) has previously been shown to inhibit thrombin clotting activity without binding to the catalytic site of the enzyme. In the present study, the effect of hirudin 54-65 on thrombin interaction with specified platelet proteins has been investigated. Hirudin 54-65 was found to inhibit thrombin-induced platelet aggregation and secretion in a dose-dependent manner. Substitution of either Phe⁵⁶, Glu⁵⁷, Ile⁵⁹, Pro⁶⁰ or Leu⁶⁴ showed that these residues were critical for inhibition of thrombin-induced platelet activation whereas sulfation of Tyr⁶³ increased the inhibitory potency of the peptide. Hydrolysis of glycoprotein V, a platelet membrane substrate for thrombin, was only partially inhibited by hirudin 54-65. Although hirudin 54-65 did not decrease the amount of thrombin bound to platelets during cross-linking experiments, it was found to inhibit the specific binding of thrombin to platelet glycoprotein Ib. Since the carboxy-terminal region of hirudin has previously been reported to bind near the trypsin-catalyzed β cleavage site, we have analyzed the consequences of a to β-thrombin conversion on both thrombin-hirudin 54-65 interaction and thrombin activity toward platelets. The β cleavage induced a decrease in the affinity of thrombin for both glycoprotein Ib and hirudin 54-65. Altogether, our results indicate that thrombin recognition sites for hirudin 54-65 and platelet membrane glycoprotein Ib share common structures located near the β cleavage site at Arg 73 on the thrombin B chain.

• References

• 1 Markwardt F. Hirudin as an inhibitor of thrombin. Methods Enzymol 1970; 19: 924-32
• 2 Bagdy D, Barabas E, Graf L, Peterson TE, Magnusson S. Hirudin. Methods Enzymol 1976; 45: 669-78
• 3 Dodt J, Köhler S, Baici A. Interaction of site specific hirudin variants with α-thrombin. FEBS Lett 1988; 229: 87-90
• 4 Dodt J, Muller HP, Seemuller U, Chang JY. The complete amino acid sequence of hirudin, a thrombin specific inhibitor. FEBS Lett 1984; 165: 180-3
• 5 Clore GM, Sukumaran DK, Nilges M, Zarbock J, Gronenborn AM. The conformation of hirudin in solution: a study using nuclear magnetic resonance, distance geometry and restrained molecular dynamics. EMBO J 1987; 6: 529-37
• 6 Chang JY. The hirudin binding site of human α-thrombin. Identification of lysyl residues which participate in the combining site of hirudin-thrombin complex. J Biol Chem 1989; 264: 7141-6
• 7 Wallace A, Dennis S, Hofsteenge J, Stone SR. Contribution of the N-terminal regions of hirudin to its interaction with thrombin. Biochemistry 1989; 28: 10079-84
• 8 Chang JY. The functional domain of hirudin, a thrombin specific inhibitor. FEBS Lett 1983; 164: 307-13
• 9 Krstenansky JL, Mao SJT. Antithrombin properties of C-terminus of hirudin using synthetic unsulfated N^α-acetyl-hirudin_45-65 . FEBS Lett 1987; 211: 10-6
• 10 Krstenansky JL, Owen TJ, Yates MT, Mao SJT. Anticoagulant peptides: nature of the interaction of the C-terminal region of hirudin with a non catalytic binding site on thrombin. J Med Chem 1987; 30: 1688-91
• 11 Maraganore JM, Chao B, Joseph ML, Jablonski J, Ramachandran KL. Anticoagulant activity of synthetic hirudin peptides. J Biol Chem 1989; 264: 8692-8
• 12 Braun PJ, Dennis S, Hofsteenge J, Stone SR. The use of site directed mutagenesis to investigate the basis for the specificity of hirudin. Biochemistry 1988; 27: 6517-22
• 13 Stone SR, Dennis S, Hofsteenge J. Quantitative evaluation of the contribution of ionic interactions to the formation of the thrombin hirudin complex. Biochemistry 1989; 28: 6857-63
• 14 Naski MC, Fenton JW, Maraganore JR, Olson ST, Shafer JA. The COOH-terminal domain of hirudin. An exosite-derived competitive inhibitor of the action of α-thrombin on fibrinogen. J Biol Chem 1990; 265: 13484-9
• 15 Grütter MG, Priestle JP, Rahuel J, Grossenbacher H, Bode W, Hofsteenge J, Stone SR. Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition. EMBO J 1990; 9: 2361-5
• 16 Rydel JR, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton JW. The structure of a complex of recombinant hirudin and human α-thrombin. Science 1990; 249: 277-80
• 17 Detwiler TC. Hypothetical models for the thrombin-platelet interaction. Ann NY Acad Sci 1981; 370: 67-71
• 18 Hoffmann A, Markwardt F. Inhibition of the thrombin-platelet reaction by hirudin. Haemostasis 1984; 14: 164-9
• 19 Jandrot-Perrus M, Didry D, Guillin MC, Nurden AT. Cross-linking of α- and γ-thrombin to distinct binding sites on human platelet. Eur J Biochem 1988; 174: 359-67
• 20 Jandrot-Perrus M, Rendu F, Caen JP, Levy-Toledano S, Guillin MC. The common pathway for a and γ-thrombin induced platelet activation is independent of GPIb: a study of Bernard-Soulier platelets. Br J Haematol 1990; 74: 385-92
• 21 McGowan EB, Detwiler TC. Modified platelet responses to thrombin. Evidence for two types of receptors or coupling mechanisms. J Biol Chem 1986; 261: 739-46
• 22 Bezeaud A, Guillin MC. Enzymic and non-enzymic properties of human β-thrombin. J Biol Chem 1988; 263: 3576-81
• 23 Fenton JW, Landis BM, Walz DA, Finlayson JS. Human thrombins. In: Chemistry and Biology of Thrombin.. Lundblad RL, Fenton JW, Mann KG. (eds) Ann Arbor Science Publishers, Ann Arbor, MI: 1977. pp 43-70
• 24 Nurden AT, Dupuis D, Kunicki TJ, Caen JP. Analysis of the glycoprotein and protein composition of Bernard-Soulier platelets by single and two dimensional gel electrophoresis. J Clin Invest 1981; 67: 1431-40
• 25 Steiner B, Clementson KJ, Luscher EF. Improvement of the periodate-borohydride surface-labeling method for human blood platelets. Thromb Res 1983; 29: 43-52
• 26 Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry 1986; 25: 4622-8
• 27 Fenton JW, Olson TA, Zabinski MP, Wilner GD. Anion-binding exosite of human α-thrombin and fibrin(ogen) recognition. Biochemistry 1988; 27: 7106-12
• 28 Stone SR, Braun PJ, Hofsteenge J. Identificaton of regions of α-thrombin involved in its interaction with hirudin. Biochemistry 1987; 26: 4617-24
• 29 Noe G, Hofsteenge J, Rovelli G, Stone SR. The use of sequence-specific antibodies to identify a secondary binding site in thrombin. J Biol Chem 1988; 263: 11729-35
• 30 Dodt J, Kohler S, Schmitz T, Wilhelm B. Distinct binding sites of Ala⁴⁸-hirudin^1-47 and Ala⁴⁸-hirudin^48-65 on α-thrombin. J Biol Chem 1990; 265: 713-8
• 31 Jakubowski JA, Maraganore JM. Inhibition of coagulation and thrombin induced platelet activities by a synthetic dodecapeptide modeled on the carboxy terminus of hirudin. Blood 1990; 75: 399-406
• 32 Phillips DR, Agin PP. Platelet membrane glycoproteins: identification of a proteolytic substrate for thrombin. Biochem Biophys Res Commun 1977; 75: 940-7
• 33 Bienz D, Schnippering W, Clemetson KJ. Glycoprotein V is not the thrombin activation receptor on human blood platelets. Blood 1986; 68: 720-5
• 34 Jandrot-Perrus M, Guillin MC, Nurden AT. Human y-thrombin: lack of correlation between a platelet functional response and glycoprotein V hydrolysis. Thromb Haemostas 1987; 58: 915-20
• 35 Gronke RS, Knauer DJ, Veeraraghavan S, Baker JF. A form of protease-nexin I is expressed on the platelet surface during platelet activation. Blood 1989; 73: 472-8
• 36 Wicki AW, Clemetson KJ. Structure and function of platelet membrane glycoproteins Ib and V. Effects of leucocyte elastase and other proteases on platelet response to von Willebrand factor and thrombin. Eur J Biochem 1985; 153: 1-11
• 37 Lopez JA, Chung DW, Fujikawa K, Hagen FS, Papayannopoulou T, Roth G. Cloning of the α-chain of human platelet glycoprotein Ib: a transmembrane protein with homology to leucine-rich-α₂ glycoprotein. Proc Natl Acad Sci USA 1987; 84: 5615-9
• 38 Titani K, Takio K, Manda M, Ruggeri Z. Amino acid sequence of the von Willebrand factor-binding domain of platelet membrane glycoprotein Ib. Proc Natl Acad Sci USA 1987; 84: 5610-4
• 39 Katagiri Y, Hayashi Y, Yamamoto K, Tanoue K, Kosaki G, Yamazaki H. Localisaton of von Willebrand factor and thrombin-interactive domains on human platelet glycoprotein Ib. Thromb Haemostas 1990; 63: 122-6
• 40 Brower MS, Walz DA, Garry KE, Fenton JW. Human neutrophil elastase alters human α-thrombin function: limited proteolysis near the γ-cleavage site results in decreased fibrinogen clotting and platelet-stimulatory activity. Blood 1987; 69: 813-9
• 41 Hofsteenge J, Braun PJ, Stone SR. Enzymatic properties of proteolytic derivatives of human α-thrombin. Biochemistry 1988; 27: 2144-51
• 42 Brezniak DV, Brower MS, Witting JI, Walz DA, Fenton JW. Human a to ζ-thrombin cleavage occurs with neutrophil cathepsin G or chymotrypsin while fibrinogen clotting activity is retained. Biochemistry 1990; 29: 3536-42
• 43 Bar-Shavit R, Hruska KA, Kahn AJ, Wilner GD. Hormone-like activity of human thrombin. Ann NY Acad Sci 1986; 485: 335-48